Cargando…
2752. Outcomes of Patients with Stenotrophomonas maltophilia infections treated with Cefiderocol in PROVE (Retrospective Cefiderocol Chart Review) Study
BACKGROUND: Gram-negative (GN) bacterial resistance remains an urgent global health problem. Cefiderocol (CFDC) has activity against Stenotrophomonas maltophilia (SM) isolates. PROVE is an ongoing international, retrospective study of CFDC use in GN infections (GNI). This report gives the first desc...
Autores principales: | Marcella, Stephen, Friedman, Bruce, Cai, Bin, Verardi, Stefano, Gozalo, Laurence, Nguyen, Sean T |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10677458/ http://dx.doi.org/10.1093/ofid/ofad500.2363 |
Ejemplares similares
-
2750. Pseudomonas aeruginosa infections treated with cefiderocol: associations of site of infection and time to first dose with outcomes in PROVE (Retrospective Cefiderocol Chart Review) Study
por: Marcella, Stephen, et al.
Publicado: (2023) -
In Vitro Activity and In Vivo Efficacy of Cefiderocol against Stenotrophomonas maltophilia
por: Nakamura, Rio, et al.
Publicado: (2021) -
Successful Treatment of Persistent Stenotrophomonas maltophilia Bacteremia With Cefiderocol in an Infant
por: Hsu, Alice J, et al.
Publicado: (2023) -
Efficacy of Cefiderocol in Experimental Stenotrophomonas maltophilia Pneumonia in Persistently Neutropenic Rabbits
por: Petraitis, Vidmantas, et al.
Publicado: (2022) -
Cefiderocol for Stenotrophomonas maltophilia prosthetic
joint infection: a case report
por: Chambers, MaKenzie M., et al.
Publicado: (2023)